For the first time, cloning technologies have been used to generate stem cells that are genetically matched to adult patients.

Fear not: No legitimate scientist is in the business of cloning humans. But cloned embryos can be used as a source for stem cells that match a patient and can produce any cell type in that person.

Researchers in two studies published this month have created human embryos for this purpose. Usually an embryo forms when sperm fertilizes egg; in this case, scientists put the nucleus of an adult skin cell inside an egg, and that reconstructed egg went through the initial stages of embryonic development.

This is a dream that weve had for 15 years or so in the stem cell field, said John Gearhart, director of the Institute for Regenerative Medicine at the University of Pennsylvania. Gearhart first proposed this approach for patient-specific stem cell generation in the 1990s but was not involved in the recent studies.

Stem cells have the potential to develop into any kind of tissue in the human body. From growing organs to treating diabetes, many future medical advances are hoped to arise from stem cells.

Scientists wrote in the journal Cell Stem Cell this month that they used skin cells from a man, 35, and another man, 75, to create stem cells from cloned embryos.

We reaffirmed that it is possible to produce patient-specific stem cells using a nuclear transfer technology regardless of the patients age, said co-lead author Young Gie Chung at the CHA Stem Cell Institute in Seoul, South Korea.

On Monday, an independent group led by scientists at the New York Stem Cell Foundation Research Institute published results in Nature using a similar approach. They used skin cells from a 32-year-old woman with Type 1 diabetes to generate stem cells matched to her.

Both new reports follow the groundbreaking research published last year by Shoukhrat Mitalipov and colleagues at Oregon Health & Science University in the journal Cell. In that study, researchers produced cloned embryos and stem cells using skin cells from a fetus and an 8-month-old baby.

Its a remarkable process that gives us these master cells, these stems cells that are essentially the seeds for all of the tissues in our bodies, said George Daley, director of the Stem Cell Transplantation Program at Boston Childrens Hospital, who was not involved in the recent studies. Thats why its so important for medical research.

Read more here:
Cloning used to make stem cells from adult humans

For the first time, cloning technologies have been used to generate stem cells that are genetically matched to adult patients.

Fear not: No legitimate scientist is in the business of cloning humans. But cloned embryos can be used as a source for stem cells that match a patient and can produce any cell type in that person.

Researchers in two studies published this month have created human embryos for this purpose. Usually an embryo forms when sperm fertilizes egg; in this case, scientists put the nucleus of an adult skin cell inside an egg, and that reconstructed egg went through the initial stages of embryonic development.

"This is a dream that we've had for 15 years or so in the stem cell field," said John Gearhart, director of the Institute for Regenerative Medicine at the University of Pennsylvania. Gearhart first proposed this approach for patient-specific stem cell generation in the 1990s but was not involved in the recent studies.

Stem cells have the potential to develop into any kind of tissue in the human body. From growing organs to treating diabetes, many future medical advances are hoped to arise from stem cells.

Scientists wrote in the journal Cell Stem Cell this month that they used skin cells from a man, 35, and another man, 75, to create stem cells from cloned embryos.

"We reaffirmed that it is possible to produce patient-specific stem cells using a nuclear transfer technology regardless of the patient's age," said co-lead author Young Gie Chung at the CHA Stem Cell Institute in Seoul, South Korea.

On Monday, an independent group led by scientists at the New York Stem Cell Foundation Research Institute published results in Nature using a similar approach. They used skin cells from a 32-year-old woman with Type 1 diabetes to generate stem cells matched to her.

Both new reports follow the groundbreaking research published last year by Shoukhrat Mitalipov and colleagues at Oregon Health & Science University in the journal Cell. In that study, researchers produced cloned embryos and stem cells using skin cells from a fetus and an 8-month-old baby.

"It's a remarkable process that gives us these master cells, these stems cells that are essentially the seeds for all of the tissues in our bodies," said George Daley, director of the Stem Cell Transplantation Program at Boston Children's Hospital, who was not involved in the recent studies. "That's why it's so important for medical research."

More:
Cloning used to make stem cells from adults

Stem Cell Treatment In Panama Working Wonders
This is an update on Beverly after only 10 days in Panama for Stem Cell Treatment. She is feeling so much better and you can see it just by the look on her face. She has Secondary Progressive...

By: Stem Cell Patient

See the original post here:
Stem Cell Treatment In Panama Working Wonders - Video

Chaiwat Subprasom/Reuters/Corbis

Many companies around the world offer stem-cell treatments to patients with heart disease.

An analysis of clinical studies that use adult stem cells to treat heart disease has raised questions about the value of a therapy that many consider inappropriately hyped.

Early-phase clinical trials have reported that adult stem cells are effective in treating heart attack and heart failure, and many companies are moving quickly to tap into this potentially lucrative market. But a comprehensive study that looked at discrepancies in trials investigating treatments that use patients own stem cells, published this week in the journal BMJ (ref. 1), finds that only trials containing flaws, such as design or reporting errors, showed positive outcomes. Error-free trials showed no benefit at all.

The publication comes as two major clinical trials designed to conclusively test the treatments efficacy are recruiting thousands of patients.

The BMJ paper is concerning because the therapeutic approach is already being commercialized, argues stem-cell researcher Paolo Bianco at the Sapienza University of Rome. Premature trials can create unrealistic hopes for patients, and divert resources from the necessary basic studies we need to design more appropriate treatments.

Therapies that use adult stem cells typically involve collecting mesenchymal stem cells from bone marrow taken from the patients hip bone. The cells are then injected back into the patient, to help repair damaged tissue. Original claims that they differentiated into replacement cells have been rejected2, and many clinicians now believe that the cells act by releasing molecules that cause inflammation, with an attendant growth of oxygen-delivering small blood vessels, in the damaged tissue.

The approach has spawned international commercialization of various forms of the therapy, with companies offering treatments for disorders ranging from Parkinsons disease to heart failure. But the effectiveness of such therapies remains unproven.

I have a lot of hope for regenerative medicine, but our results make me fearful.

The BMJ study, led by cardiologist Darrel Francis at Imperial College London, examined 133 reports of 49 randomized clinical trials published up to April last year, involving the treatment of patients who had had a heart attack or heart failure. It included all accessible randomized studies, and looked for discrepancies in design, methodology and reporting of results.

Excerpt from:
Doubts over heart stem-cell therapy

The King Abdullah International Medical Research Center (KAIMRC) recently joined a conference on stem cell research and its application science and medicine, the Saudi Press Agency reported. The conference, which was organized by the Health Affairs at the National Guard, unveiled the latest discoveries and findings made by researchers at the stem cell and regenerative medicine unit at KAIMRC, the agency said. The conference was attended by several experts on stem cell research representing Saudi Arabia, the United States, Britain, France, Sweden, Italy, Australia and New Zealand. Ahmed Al-Askar, CEO of KAIMRC, said stem cell research is a broad topic that sheds light on how to best exploit human cells to treat diseases for certain organs, such as the liver, kidney or nerves. He said the current use of stem cells is centered on plantation for the treatment of certain types of leukemia, cancer and genetic diseases. Since its inception three years ago, the center has transplanted 200 cells following the creation of a program for transplanting stem cells in children and adults, he said. Saudi Arabia has the sole stem cell donation registry in Arab countries, compared with 60 cells donation registries globally, he said. The Saudi stem cell donation center is meant to attract potential donors from Arab countries, he said. We have had 5,000 donors so far. He said some 400 scientists and experts are working at the center, while another 40 physicians have been dispatched on scholarships to acquire training and specialization. Al-Askar expressed optimism over the future of stem cell use and its contribution to the treatment of a variety of diseases, such as diabetes, cancer, pulmonary and hepatic fibrosis and neurological and cardiovascular disorders.

More here:
Conference to shed light on latest stem cell applications

(MENAFN - Arab News) The king abdullah international medical research center (kaimrc) recently joined a conference on stem cell research and its application science and medicine the saudi press agency reported.

the conference which was organized by the health affairs at the national guard unveiled the latest discoveries and findings made by researchers at the stem cell and regenerative medicine unit at kaimrc the agency said.

the conference was attended by several experts on stem cell research representing saudi arabia the united states britain france sweden italy australia and new zealand.

ahmed al-askar ceo of kaimrc said stem cell research is a broad topic that sheds light on how to best exploit human cells to treat diseases for certain organs such as the liver kidney or nerves.

he said the current use of stem cells is centered on plantation for the treatment of certain types of leukemia cancer and genetic diseases.

since its inception three years ago the center has transplanted 200 cells following the creation of a program for transplanting stem cells in children and adults he said.

saudi arabia has the sole stem cell donation registry in arab countries compared with 60 cells donation registries globally he said.

'the saudi stem cell donation center is meant to attract potential donors from arab countries" he said. 'we have had 5000 donors so far."

he said some 400 scientists and experts are working at the center while another 40 physicians have been dispatched on scholarships to acquire training and specialization.

al-askar expressed optimism over the future of stem cell use and its contribution to the treatment of a variety of diseases such as diabetes cancer pulmonary and hepatic fibrosis and neurological and cardiovascular disorders.

Original post:
Saudi- Conference to shed light on latest stem cell applications

Released: 4/28/2014 3:00 PM EDT Source Newsroom: City of Hope Contact Information

Available for logged-in reporters only

Newswise DUARTE, Calif. Bone marrow transplants offer a second chance for people with life-threatening blood cancers and other hematologic malignancies. But many recipients, though overwhelmed with curiosity and the need to express their gratitude, can only dream of meeting the strangers who saved their lives. City of Hope is about to make that dream come true for two patients.

At City of Hopes annual Bone Marrow Transplantation Reunion on May 9, two grateful patients will meet the strangers, each hailing from different countries, who gave them back their futures.

Shes a world away, and weve never met, but were in a way genetic twins, said George Winston, the impressionistic, genre-defying musician with more than 20 instrumental albums under his belt. Winston received a lifesaving transplant from a young German woman two years ago, and cant wait to get to know her. Its amazing how they can locate a donor. I cant wait to meet her and just thank her from the bottom of my heart.

The meetings are the public focal point of City of Hopes annual Celebration of Life. Other meetings, and reunions, will take place throughout the event, attended by more than 6,500 bone marrow, stem cell and cord blood transplant recipients, their families and donors. All will celebrate second chances, scientific breakthroughs and transplant anniversaries.

Each survivor wears a button proudly proclaiming the years since his or her transplant. For some, its only a year. For others, a few decades. They celebrate their own recoveries, and the medical advances that have allowed this fellowship of survivors to grow from just a single patient 38 years ago at the first reunion, to thousands.

City of Hope helped pioneer bone marrow transplantation nearly four decades ago and is now a leader in bone marrow, stem cell and cord blood transplant, preparing to formally launch its Hematologic Cancers Institute. City of Hope has the only transplant program in the nation to achieve nine consecutive reporting years of over performance in one-year overall patient survival, according to the most recent data from the Center for International Blood and Marrow Transplant Research, which tracks all such transplants performed in the U.S.

The reunion is a motivation that leaves us in awe of the many patients weve been able to help, but also humbled and focused on the patients currently in our care and those who will count on us in the future, said Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation. We dont have any results so good that they cannot be improved. Were always focused on how we can do this better. Were never satisfied.

Two patients will be highlighted as part of the reunion, and will meet their donors for the first time ever.

See the rest here:
Bone Marrow Recipients Get Rare Chance to Meet Their "Genetic Twins" at City of Hope

Researchers hope stem cells could one day treat chronic conditions like diabetes and Parkinsons disease.

Healthy bloom: Insulin, shown in red, is being produced by cells that started as embryonic stem cells derived from a patient with type 1 diabetes.

A series of breakthroughs in cloning technology over the last year and a half are stoking hopes that cells could be used as treatments for patients with chronic, debilitating diseases such as diabetes and Parkinsons.

In January 2013, researchers at the Oregon Health and Science University reported that they had successfully created embryonic stem cells from a human embryo formed when the nucleus of one persons cell was transferred into another persons egg that had its original nucleus removed (see Human Embryonic Stem Cells Cloned). That was the first time stem cells had been made from such a cloned embryo, and the advance provides a potential route by which scientists could create various kinds of replacement cells based on a patients own genome. Many other research teams are pursuing another method of creating stem cells from a patients own cells, but some believe cells made with the cloning technique could be more likely to develop into a wide variety of cell types.

In the most recent advance for the cloning-based approach, a new report describes stem cells produced by cloning a skin cell from a woman with type 1 diabetes. The researchers were then able to turn those stem cells into insulin-producing cells resembling the beta cells that are lost in that disease. The immune system attacks these pancreatic cells, leaving patients unable to properly regulate their blood sugar levels.

Susan Solomon, a coauthor of the new study and cofounder of the New York Stem Cell Foundation (NYSCF), told reporters the results are an important step forward in our quest to develop healthy patient-specific stem cells to be used to replace cells that are diseased or dead.

The ultimate idea is to treat diabetes with insulin-producing cells made from a patients own cells and a donated egg. Currently, insulin-producing cells harvested from a cadaver are transplanted into some diabetes patients. But patients treated this way must take immunosuppressing drugs, and the number of cadaver cells is limited.

The cloned cells are thought to be better accepted by the immune system. But given that the body attacks its own beta cells, how can researchers prevent the immune destruction of the transplants? Its very difficult, says Solomon. We are acutely aware of the need to address both sides of the problem.

There are also regulatory issues surrounding the cloning method. Lead researcher and coauthor Dieter Egli began the research at Harvard University but moved it to the New York institution because Massachusetts restrictions on egg donation prevented the work from progressing.

Egg supply is another challenge. The cloning works about 10 percent of the time, and only three of the four cloned embryos in the experiment led to viable stem-cell lines. When you think about wider application of this technology for patients with diabetes, cardiovascular disease, [and others], you are talking about hundreds of millions of people, says Robert Lanza, a stem-cell pioneer at Advanced Cell Technology and coauthor of a recent cloning report. When you start talking about numbers like that, its just not going to be practical to use these cells in that patient-specific way.

Follow this link:
Stem Cells from a Diabetes Patient

Scientists have used cloning technology to make stem cells from a woman with Type 1 diabetes that are genetically matched to her and to her disease.

They hope to someday use such cells as tailor-made transplants to treat or potentially even cure the disease, which affects millions and which now has few treatment options other than careful diet and regular use of insulin.

Its the second report his month of success in using cloning technology to make human embryonic stem cells the cells that eventually create a complete human being and that scientists hope to harness to treat diseases ranging from diabetes to Parkinsons and injuries that cause paralysis or organ damage.

I think this is going to become reality, Dr. Dieter Egli of the New York Stem Cell Foundation, whose report is published in the journal Nature on Monday, told reporters. It may be a bit in the future but it is going to happen.

The technique they use is called somatic cell nuclear transfer the same method used to make Dolly, the sheep who was the first mammal to be cloned, in 1996. Scientists remove the nucleus from a normal cell, clear the nucleus from a human egg cell, then inject the nucleus from the skin cell into the egg.

I think this is going to become reality."

Various chemical or electrical tricks can be used to start the egg growing as if it had been fertilized by sperm. In this case, they used DNA from a woman with Type 1 diabetes, and they said they used an improved method to trick the egg into developing.

It got to whats called a blastocyst a ball of cells that has not yet begun to differentiate into the different types of cells and tissues in the body, such as nerve cells, blood cells and bone cells. They removed individual cells and used various chemical baths to direct them to form into the desired cell type the beta cells in the pancreas that make insulin and that are destroyed in diabetes. These cells carry the patients own unique DNA, including whatever genetic mistakes led to her diabetes.

These stem cells could therefore be used to generate cells for therapeutic cell replacement, they wrote in their report.

Scientists have cloned sheep, pigs, mice and monkeys, but its been far harder to clone human beings. Its partly because of the controversy few people advocate cloning humans for the purpose of making babies, and many people object to destroying a human embryo, even one that only ever existed in a lab dish.

Original post:
Stem Cells Made From Cloning Diabetic Woman

Scientists have taken skin cells from a woman suffering from type 1 diabetes, reprogrammed them into embryonic stem cells, and then converted those cells into insulin-producing cells in mice, according to a new study.

The announcement, which comes soon after another stem cell success involving therapeutic cloning, was published Monday in the journal Nature.

"This advance brings us a significant step closer to the development of cell replacement therapies," said senior study author Dieter Egli, a researcher at the New York Stem Cell Foundation.

Embryonic stem cells, or pluripotent cells, are cells that can reproduce endlessly and transform themselves into any type of human tissue. Researchers hope that the cells will one day be used to create transplant tissues that will not be rejected by the patient's body, because they carry their own DNA.

Egli and his colleagues used a cloning technique known as somatic cell nuclear transfer, or SCNT -- a process similar to the one used to clone "Dolly" the sheep in 1996.

The process involves removing the nucleus from a human egg cell, replacing it with the nucleus from a foreign "donor" cell, and then allowing the egg to divide and develop for a period of days. The developing embryo will contain a mass of pluripotent cells, which are removed and used to create a line of reproducing cells.

If the cloned embryo were implanted in the womb of a surrogate mother -- an act scientists consider unethical for a number of reasons -- it could possibly develop into a baby.

Up until now, the stem cell field has relied on a very different method of pluripotent cell production called induced pluripotency. The process is viewed as being much easier than SCNT, because it does not involve the controversial use of human egg cells, which are also difficult to obtain.

At a news conference, Egli told reporters that the SCNT process was becoming increasingly refined and should be viewed as a reliable source of pluripotent cells.

"For me this is the way to go," Egli said. "This is about reprogramming a patient's own cells, with their own genotype, with their own DNA that are immunologically matched to them and no one else, essentially. I think this is going to become a reality."

See original here:
Scientists report another embryonic cloning success

Scientists have used cloning technology to make stem cells from a woman with Type 1 diabetes that are genetically matched to her and to her disease.

They hope to someday use such cells as tailor-made transplants to treat or potentially even cure the disease, which affects millions and which now has few treatment options other than careful diet and regular use of insulin.

Its the second report his month of success in using cloning technology to make human embryonic stem cells the cells that eventually create a complete human being and that scientists hope to harness to treat diseases ranging from diabetes to Parkinsons and injuries that cause paralysis or organ damage.

I think this is going to become reality, Dr. Dieter Egli of the New York Stem Cell Foundation, whose report is published in the journal Nature on Monday, told reporters. It may be a bit in the future but it is going to happen.

The technique they use is called somatic cell nuclear transfer the same method used to make Dolly, the sheep who was the first mammal to be cloned, in 1996. Scientists remove the nucleus from a normal cell, clear the nucleus from a human egg cell, then inject the nucleus from the skin cell into the egg.

I think this is going to become reality."

Various chemical or electrical tricks can be used to start the egg growing as if it had been fertilized by sperm. In this case, they used DNA from a woman with Type 1 diabetes, and they said they used an improved method to trick the egg into developing.

It got to whats called a blastocyst a ball of cells that has not yet begun to differentiate into the different types of cells and tissues in the body, such as nerve cells, blood cells and bone cells. They removed individual cells and used various chemical baths to direct them to form into the desired cell type the beta cells in the pancreas that make insulin and that are destroyed in diabetes. These cells carry the patients own unique DNA, including whatever genetic mistakes led to her diabetes.

These stem cells could therefore be used to generate cells for therapeutic cell replacement, they wrote in their report.

Scientists have cloned sheep, pigs, mice and monkeys, but its been far harder to clone human beings. Its partly because of the controversy few people advocate cloning humans for the purpose of making babies, and many people object to destroying a human embryo, even one that only ever existed in a lab dish.

Excerpt from:
Diabetic Woman's Cells Are Turned Into Embryonic Stem Cells

Cell lines made by two separate teams could boost the prospects of patient-specific therapies

This colony of embryonic stem cells, created from a type 1 diabetes patient, is one of the first to be cloned from an adult human. Credit:Bjarki Johannesson, NYSCF

Two research groups have independently produced human embryonic stem-cell lines from embryos cloned from adult cells. Their success could reinvigorate efforts to use such cells to make patient-specific replacement tissues for degenerative diseases, for example to replace pancreatic cells in patients with type 1 diabetes. But further studies will be needed before such cells can be tested as therapies.

The first stem-cell lines from cloned human embryos were reported in May last year by a team led by reproductive biology specialist Shoukhrat Mitalipov of the Oregon Health & Science University in Beaverton (see 'Human stem cells created by cloning'). Those cells carried genomes taken from fetal cells or from cells of an eight-month-old baby, and it was unclear whether this would be possible using cells from older individuals. (Errors were found in Mitalipov's paper, but were not deemed to affect the validity of its results.)

Now two teams have independently announced success. On 17 April, researchers led by Young Gie Chung and Dong Ryul Lee at the CHA University in Seoul reported inCell Stem Cellthat they had cloned embryonic stem-cell (ES cell) lines made using nuclei from two healthy men, aged 35 and 75. And in a paper published onNature's website today, a team led by regenerative medicine specialist Dieter Egli at the New York Stem Cell Foundation Research Institute describes ES cells derived from a cloned embryo containing the DNA from a 32-year-old woman with type 1 diabetes. The researchers also succeeded in differentiating these ES cells into insulin-producing cells.

Nuclear transfer To produce the cloned embryos, all three groups used an optimized version of the laboratory technique called somatic-cell nuclear transfer (SCNT), where the nucleus from a patient's cell is placed into an unfertilized human egg which has been stripped of its own nucleus. This reprograms the cell into an embryonic state. SCNT was the technique used to create the first mammal cloned from an adult cell, Dolly the sheep, in 1996.

The studies show that the technique works for adult cells and in multiple labs, marking a major step. It's important for several reasons, says Robin Lovell-Badge, a stem-cell biologist at the MRC National Institute for Medical Research in London.

At present, studies to test potential cell therapies derived from ES cells are more likely to gain regulatory approval than those testing therapies derived from induced pluripotent stem (iPS) cells, which are made by adding genes to adult cells to reprogram them to an embryonic-like state. Compared with iPS cells, ES cells are less variable, says Lovell-Badge. Therapies for spinal-cord injury and eye disease using non-cloned ES cells have already been tested in human trials. But while many ES cell lines have been made using embryos left over from fertility treatments, stem cells made from cloned adult cells are genetically matched to patients and so are at less risk of being rejected when transplanted.

Ethically fraught Lovell-Badge says cloned embryos could also be useful in other ways, in particular to improve techniques for reprogramming adult cells and to study cell types unique to early-stage embryos, such as those that go on to form the placenta.

Few, however, expect a huge influx of researchers making stem cells from cloned human embryos. The technique is expensive, technically difficult and ethically fraught. It creates an embryo only for the purpose of harvesting its cells. Obtaining human eggs also requires regulatory clearance to perform an invasive procedure on healthy young women, who are paid for their time and discomfort.

Read the original here:
Stem Cells Made from Cloned Human Embryos

Bjarki Johannesson, NYSCF

This colony of embryonic stem cells, created from a type 1 diabetes patient, is one of the first to be cloned from an adult human.

Two research groups have independently produced human embryonic stem-cell lines from embryos cloned from adult cells. Their success could reinvigorate efforts to use such cells to make patient-specific replacement tissues for degenerative diseases, for example to replace pancreatic cells in patients with type 1 diabetes. But further studies will be needed before such cells can be tested as therapies.

The first stem-cell lines from cloned human embryos were reported in May last year by a team led by reproductive biology specialist Shoukhrat Mitalipov of the Oregon Health & Science University in Beaverton (see 'Human stem cells created by cloning'). Those cells carried genomes taken from fetal cells or from cells of an eight-month-old baby1, and it was unclear whether this would be possible using cells from older individuals. (Errors were found in Mitalipov's paper, but were not deemed to affect the validity of its results.)

Now two teams have independently announced success. On 17 April, researchers led by Young Gie Chung and Dong Ryul Lee at the CHA University in Seoul reported inCell Stem Cell that they had cloned embryonic stem-cell (ES cell) lines made using nuclei from two healthy men, aged 35 and 752. And in a paper published on Nature's website today, a team led by regenerative medicine specialist Dieter Egli at the New York Stem Cell Foundation Research Institute describes ES cells derived from a cloned embryo containing the DNA from a 32-year-old woman with type 1 diabetes. The researchers also succeeded in differentiating these ES cells into insulin-producing cells3.

To produce the cloned embryos, all three groups used an optimized version of the laboratory technique called somatic-cell nuclear transfer (SCNT), where the nucleus from a patient's cell is placed into an unfertilized human egg which has been stripped of its own nucleus. This reprograms the cell into an embryonic state. SCNT was the technique used to create the first mammal cloned from an adult cell, Dolly the sheep, in 1996.

The studies show that the technique works for adult cells and in multiple labs, marking a major step. It's important for several reasons, says Robin Lovell-Badge, a stem-cell biologist at the MRC National Institute for Medical Research in London.

At present, studies to test potential cell therapies derived from ES cells are more likely to gain regulatory approval than those testing therapies derived from induced pluripotent stem (iPS) cells, which are made by adding genes to adult cells to reprogram them to an embryonic-like state. Compared with iPS cells, ES cells are less variable, says Lovell-Badge. Therapies for spinal-cord injury and eye disease using non-cloned ES cells have already been tested in human trials. But while many ES cell lines have been made using embryos left over from fertility treatments, stem cells made from cloned adult cells are genetically matched to patients and so are at less risk of being rejected when transplanted.

Lovell-Badge says cloned embryos could also be useful in other ways, in particular to improve techniques for reprogramming adult cells and to study cell types unique to early-stage embryos, such as those that go on to form the placenta.

Few, however, expect a huge influx of researchers making stem cells from cloned human embryos. The technique is expensive, technically difficult and ethically fraught. It creates an embryo only for the purpose of harvesting its cells. Obtaining human eggs also requires regulatory clearance to perform an invasive procedure on healthy young women, who are paid for their time and discomfort.

Original post:
Stem cells made by cloning adult humans

Using somatic cell nuclear transfer, a team of scientists led by Dr. Dieter Egli at the New York Stem Cell Foundation (NYSCF) Research Institute and Dr. Mark Sauer at Columbia University Medical Center has created the first disease-specific embryonic stem cell line with two sets of chromosomes.

As reported today in Nature, the scientists derived embryonic stem cells by adding the nuclei of adult skin cells to unfertilized donor oocytes using a process called somatic cell nuclear transfer (SCNT). Embryonic stem cells were created from one adult donor with type 1 diabetes and a healthy control. In 2011, the team reported creating the first embryonic cell line from human skin using nuclear transfer when they made stem cells and insulin-producing beta cells from patients with type 1 diabetes. However, those stem cells were triploid, meaning they had three sets of chromosomes, and therefore could not be used for new therapies.

The investigators overcame the final hurdle in making personalized stem cells that can be used to develop personalized cell therapies. They demonstrated the ability to make a patient-specific embryonic stem cell line that has two sets of chromosomes (a diploid state), the normal number in human cells. Reports from 2013 showed the ability to reprogram fetal fibroblasts using SCNT; however, this latest work demonstrates the first successful derivation by SCNT of diploid pluripotent stem cells from adult and neonatal somatic cells.

"From the start, the goal of this work has been to make patient-specific stem cells from an adult human subject with type 1 diabetes that can give rise to the cells lost in the disease," said Dr. Egli, the NYSCF scientist who led the research and conducted many of the experiments. "By reprograming cells to a pluripotent state and making beta cells, we are now one step closer to being able to treat diabetic patients with their own insulin-producing cells."

"I am thrilled to say we have accomplished our goal of creating patient-specific stem cells from diabetic patients using somatic cell nuclear transfer," said Susan L. Solomon, CEO and co-founder of NYSCF. "I became involved with medical research when my son was diagnosed with type 1 diabetes, and seeing today's results gives me hope that we will one day have a cure for this debilitating disease. The NYSCF laboratory is one of the few places in the world that pursues all types of stem cell research. Even though many people questioned the necessity of continuing our SCNT work, we felt it was critical to advance all types of stem-cell research in pursuit of cures. We don't have a favorite cell type, and we don't yet know what kind of cell is going to be best for putting back into patients to treat their disease."

The research is the culmination of an effort begun in 2006 to make patient-specific embryonic stem cell lines from patients with type 1 diabetes. Ms. Solomon opened NYSCF's privately funded laboratory on March 1, 2006, to facilitate the creation of type 1 diabetes patient-specific embryonic stem cells using SCNT. Initially, the stem cell experiments were done at Harvard and the skin biopsies from type 1 diabetic patients at Columbia; however, isolation of the cell nuclei from these skin biopsies could not be conducted in the federally funded laboratories at Columbia, necessitating a safe-haven laboratory to complete the research. NYSCF initially established its lab, now the largest independent stem cell laboratory in the nation, to serve as the site for this research.

In 2008, all of the research was moved to the NYSCF laboratory when the Harvard scientists determined they could no longer move forward, as restrictions in Massachusetts prevented their obtaining oocytes. Dr. Egli left Harvard University and joined NYSCF; at the same time, NYSCF forged a collaboration with Dr. Sauer who designed a unique egg-donor program that allowed the scientists to obtain oocytes for the research.

"This project is a great example of how enormous strides can be achieved when investigators in basic science and clinical medicine collaborate. I feel fortunate to have been able to participate in this important project," said Dr. Sauer. Dr. Sauer is vice chair of the Department of Obstetrics and Gynecology, professor of obstetrics and gynecology, and chief of reproductive endocrinology at Columbia University Medical Center and program director of assisted reproduction at the Center for Women's Reproductive Care.

Patients with type 1 diabetes lack insulin-producing beta cells, resulting in insulin deficiency and high blood-sugar levels. Therefore, producing beta cells from stem cells for transplantation holds promise as a treatment and potential cure for type 1 diabetes. Because the stem cells are made using a patient's own skin cells, the beta cells for replacement therapy would be autologous, or from the patient, matching the patient's DNA.

Generating autologous beta cells using SCNT is only the first step in developing a complete cell replacement therapy for type 1 diabetes. In type 1 diabetes, the body's immune system attacks its own beta cells; therefore, further work is underway at NYSCF, Columbia, and other institutions to develop strategies to protect existing and therapeutic beta cells from attack by the immune system, as well as to prevent such attack.

More:
First disease-specific human embryonic stem cell line by nuclear transfer

Regenerative medicine took a step forward on Monday with the announcement of the creation of the first disease-specific line of embryonic stem cells made with a patient's own DNA.

These cells, which used DNA from a 32-year-old woman who had developed Type-1 diabetes at the age of ten, might herald the daystill far in the futurewhen scientists replace dysfunctional cells with healthy cells identical to the patient's own but grown in the lab.

The work was led by Dieter Egli of the New York Stem Cell Foundation (NYSCF) and was published Monday in Nature.

"This is a really important step forward in our quest to develop healthy, patient-specific stem cells that can be used to replace cells that are diseased or dead," said Susan Solomon, chief executive officer of NYSCF, which she co-founded in 2005 partly to search for a cure for her son's diabetes.

Stem cells could one day be used to treat not only diabetes but also other diseases, such as Parkinson's and Alzheimer's.

Embryonic Stem Cells Morph Into Beta Cells

In Type 1 diabetes, the body loses its ability to produce insulin when insulin-producing beta cells in the pancreas become damaged. Ideally this problem could be corrected with replacement therapy, using stem cells to create beta cells the body would recognize as its own because they contain the patient's own genome. This is the holy grail of personalized medicine.

To create a patient-specific line of embryonic stem cells, Egli and his colleagues used a technique known as somatic cell nuclear transfer. They took skin cells from the female patient, removed the nucleus from one cell and then inserted it into a donor egg cellan oocytefrom which the nucleus had been removed.

They stimulated the egg to grow until it became a blastocyst, a hundred-cell embryo in which some cells are "pluripotent," or capable of turning into any type of cell in the body. The researchers then directed a few of those embryonic stem cells to become beta cells. To their delight, the beta cells in the lab produced insulin, just as they would have in the body.

This research builds on work done last year in which scientists from the Oregon Health and Science University used the somatic cell nuclear transfer technique with skin cells from a fetus. It also advances previous work done by Egli and his colleagues in 2011, in which they created embryonic stem cell lines with an extra set of chromosomes. (The new stem cells, and the ones from Oregon, have the normal number of chromosomes.)

Originally posted here:
Scientists Create Personalized Stem Cells, Raising Hopes for Diabetes Cure

Stem cell therapy | irish stem cells
http://www.arthritistreatmentcenter.com So what #39;s going on in Ireland when it comes to arthritis... coming up next... First signs of arthritis cure seen by I...

By: Nathan Wei

Read the original here:
Stem cell therapy | irish stem cells - Video

Stem cell therapies work as a complement to standard treatments, potentially cutting the number of deaths after a year, suggests evidence from the latest Cochrane review: Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Taking stem cells from a patients bone marrow and injecting them into their damaged heart may be an effective way to treat heart disease.

The new review, published in The Cochrane Library, uses data involving 1,255 people from 23 randomised controlled trials, where all participants received standard treatments. Compared to standard treatment alone or with placebo, stem cell therapy using bone marrow cells resulted in fewer deaths due to heart disease and heart failure, reduced the likelihood of patients being readmitted to hospital, and improved heart function. However, researchers say that with much larger clinical trials underway, the findings are awaited to enable more certainty about the effects.

Dr Enca Martin-Rendon, author of the review, Cochrane Heart Review Group, and based at NHS Blood and Transplant and the University of Oxford, UK, said: This is encouraging evidence that stem cell therapy has benefits for heart disease patients. However, it is generated from small studies and it is difficult to come to any concrete conclusions until larger clinical trials that look at longer- term effects are carried out.

Stem cell therapies are experimental treatments that are currently only available in facilities carrying out medical research. If eventually found to be effective, they might offer an alternative or complementary treatment to standard drug and surgical treatments for some patients with chronic heart disease. The procedure involves collecting stem cells from a patient's own blood or bone marrow and using them to repair damaged tissues in the patient's heart and arteries.

Although within the first year there were no clear benefits of stem cell therapy over standard treatment alone, when longer term data were analysed a year or more later about 3 per cent of people treated with their stem cells had died compared with 15 per cent of people in the control groups. Hospital readmissions were reduced to 2 in every 100 people compared to 9 in the control group, and adverse effects were rare.

Dr Martin-Rendon continued, It isn't clear which types of stem cells work best or why stem cell therapies seem to work for some people but not for others. We need to find out what's different in the people who aren't responding well to these treatments as it might then be possible to tailor therapies to these patients, so that they work better."

Dr David Tovey, Editor-in-Chief, Cochrane, said: This review should help to raise awareness of the potential of stem cell therapy to improve patient outcomes, but it also demonstrates the importance of recognising the uncertainty of initial findings and the need for further research. A Cochrane review aims to analyse all available data to give a clear picture of what the evidence shows. Ensuring health decision makers, health professionals and the general public has access to up-to-date, relevant evidence research will help to raise awareness of the effectiveness of treatments and medications and therefore improve health care.

Cochrane Library

Read the rest here:
Stem Cell Therapies Look Promising For Heart Disease

PUBLIC RELEASE DATE:

28-Apr-2014

Contact: Franca Davenport f.davenport@imperial.ac.uk 020-759-42198 Imperial College London

New research looking at the success of clinical trials of stem cell therapy shows that trials appear to be more successful in studies where there are more discrepancies in the trial data.

Researchers from Imperial College London conducted a meta-analysis of 49 randomised controlled trials of bone marrow stem cell therapy for heart disease. The study, published today in the British Medical Journal, identified and listed over 600 discrepancies within the trial reports.

Discrepancies were defined as two (or more) reported facts that could not both be accurate because they were logically or mathematically incompatible. For example, one trial reported that it involved 70 patients, who were divided into two groups of 35 and 80.

The researchers found eight trials that each contained over 20 discrepancies.

The researchers found that the discrepancy count in a trial was the most important determinant of the improvement in cardiac function reported by that trial. Trials with fewer and fewer discrepancies showed progressively smaller improvements in cardiac function. The five trials with no discrepancies at all showed an effect size of zero (see bar chart in Notes to Editors).

Previous meta-analyses looking at the results of lots of clinical trials have suggested that on average, bone marrow stem cell therapy has a significant positive effect on improving heart function. However, some trials have shown that it successfully improves heart function whilst others have not. The reasons for this are unclear.

Professor Darrel Francis, one of the study authors from the National Heart and Lung Institute at Imperial College London, said: "Clinical trials involve a huge amount of data and so it is understandable that discrepancies sometimes arise when researchers are presenting their findings. However, our study suggests that these discrepancies can have a significant impact on the overall results. It is a powerful reminder to all of us conducting clinical trials to be careful and vigilant to avoid discrepancies appearing in the work.

See the rest here:
Study of stem cell trials links discrepancies in data with reported success of treatment

New York, NY (PRWEB) April 29, 2014

The Stem Cell Institute located in Panama City, Panama, welcomes special guest speaker Roberta F. Shapiro, DO, FAAPM&R to its public seminar on umbilical cord stem cell therapy on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Dr. Shapiro will discuss A New York Doctors Path to Panama.

Dr. Shapiro operates a private practice for physical medicine and rehabilitation in New York City. Her primary professional activities include outpatient practice focused on comprehensive treatment of acute and chronic musculoskeletal and myofascial pain syndromes using manipulation techniques, trigger point injections, tendon injections, bursae injections, nerve and motor point blocks. Secondary work at her practice focuses on the management of pediatric onset disability.

She is the founder and president of the Dayniah Fund, a non-profit charitable foundation formed to support persons with progressive debilitating diseases who are faced with catastrophic events such as surgery or illness. The Dayniah Fund educates the public about the challenges of people with disabilities and supports research on reducing the pain and suffering caused by disabling diseases and conditions.

Dr. Shapiro serves as assistant clinical professor in the Department of Rehabilitation and Regenerative Medicine at Columbia University Medical Center.

Stem Cell Institute Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Read more:
Stem Cell Institute Welcomes Special Guest Speaker Roberta F. Shapiro DO, FAAPM&R to Stem Cell Therapy Public Seminar ...

SAN FRANCISCO, April 28 (UPI) -- An international team of researchers developed skin grown from human stem cells that may eliminate using animals for drug and cosmetics testing and help develop news therapies for skin disorders.

The team led by Kings College London and the San Francisco Veteran Affairs Medical Center developed the first laboratory-grown epidermis -- the outer layer of skin -- similar to real skin.

"The ability to obtain an unlimited number of genetically identical units can be used to study a range of conditions where the skins barrier is defective due to mutations in genes involved in skin barrier formation, such as ichthyosis (dry, flaky skin) or atopic dermatitis, (eczema)," Dr. Theodora Mauro, leader of the San Francisco Veteran Affairs Medical Center team, said in a statement.

"We can use this model to study how the skin barrier develops normally, how the barrier is impaired in different diseases and how we can stimulate its repair and recovery."

The new skin is grown from human pluripotent stem cells -- stem cells that have the potential to differentiate into almost any cell in the body. Under the right circumstances, the stem cell can produce almost all of the cells in the body.

The human induced pluripotent stem cells can produce an unlimited supply of pure keratinocytes, the predominant cell type in the outermost layer of skin that closely match keratinocytes generated from human embryonic stem cells.

The artificial skin forms a protective barrier between the body and the environment keeping out microbes and toxins, while not allowing water from escaping the body.

The findings were published in the journal Stem Cell Reports.

Read the original post:
Researchers create artificial skin using stem cells